new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 475 hits with Last Name = 'taddei' and Initial = 'dm'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205257
PNG
(US9249125, 10)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4cccc(CN5CCCC5=O)c4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C41H40N10O3/c1-25-19-28(21-27-23-43-48-38(25)27)44-39-42-17-16-36(47-39)54-33-15-14-32(30-11-5-6-12-31(30)33)45-40(53)46-35-22-34(41(2,3)4)49-51(35)29-10-7-9-26(20-29)24-50-18-8-13-37(50)52/h5-7,9-12,14-17,19-23H,8,13,18,24H2,1-4H3,(H,43,48)(H,42,44,47)(H2,45,46,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205262
PNG
(US9249125, 15)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)nc1
Show InChI InChI=1S/C40H41N11O4/c1-40(2,3)34-23-35(51(49-34)28-9-13-36(42-25-28)54-21-18-50-16-19-53-20-17-50)46-39(52)45-32-11-12-33(30-7-5-4-6-29(30)32)55-37-14-15-41-38(47-37)44-27-8-10-31-26(22-27)24-43-48-31/h4-15,22-25H,16-21H2,1-3H3,(H,43,48)(H,41,44,47)(H2,45,46,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205293
PNG
(US9249125, 46)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]nc(C(=O)N(C)C)c4c3)n2)c2ccccc12)C(C)C
Show InChI InChI=1S/C38H36N10O4/c1-22(2)31-21-33(48(46-31)24-11-13-25(51-5)14-12-24)42-38(50)41-29-16-17-32(27-9-7-6-8-26(27)29)52-34-18-19-39-37(43-34)40-23-10-15-30-28(20-23)35(45-44-30)36(49)47(3)4/h6-22H,1-5H3,(H,44,45)(H,39,40,43)(H2,41,42,50)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205294
PNG
(US9249125, 47)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]nc(C(=O)N(C)C)c4c3)n2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C39H38N10O4/c1-39(2,3)32-22-33(49(47-32)24-12-14-25(52-6)15-13-24)43-38(51)42-29-17-18-31(27-10-8-7-9-26(27)29)53-34-19-20-40-37(44-34)41-23-11-16-30-28(21-23)35(46-45-30)36(50)48(4)5/h7-22H,1-6H3,(H,45,46)(H,40,41,44)(H2,42,43,51)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205297
PNG
(US9249125, 50)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CC(=O)Nc5c4)n3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C42H43N9O5/c1-42(2,3)36-26-37(51(49-36)29-7-6-8-30(25-29)55-22-19-50-17-20-54-21-18-50)47-41(53)46-33-13-14-35(32-10-5-4-9-31(32)33)56-39-15-16-43-40(48-39)44-28-12-11-27-23-38(52)45-34(27)24-28/h4-16,24-26H,17-23H2,1-3H3,(H,45,52)(H,43,44,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205298
PNG
(US9249125, 51)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C41H41N9O4/c1-27(2)37-25-40(50(48-37)30-6-5-7-31(23-30)53-21-18-49-16-19-52-20-17-49)46-41(51)45-36-12-13-38(34-9-4-3-8-33(34)36)54-32-14-15-42-39(24-32)44-29-10-11-35-28(22-29)26-43-47-35/h3-15,22-27H,16-21H2,1-2H3,(H,42,44)(H,43,47)(H2,45,46,51)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205302
PNG
(US9249125, 55)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4cc(C)c5[nH]ncc5c4)n3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C41H42N10O4/c1-26(2)35-24-37(51(49-35)30-7-6-8-31(23-30)54-20-17-50-15-18-53-19-16-50)46-41(52)45-34-11-12-36(33-10-5-4-9-32(33)34)55-38-13-14-42-40(47-38)44-29-21-27(3)39-28(22-29)25-43-48-39/h4-14,21-26H,15-20H2,1-3H3,(H,43,48)(H,42,44,47)(H2,45,46,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205305
PNG
(US9249125, 58)
Show SMILES CN(C)CCOc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3cc(C)c4[nH]ncc4c3)c2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C41H43N9O3/c1-26-21-28(22-27-25-43-47-39(26)27)44-37-23-31(17-18-42-37)53-35-16-15-34(32-9-7-8-10-33(32)35)45-40(51)46-38-24-36(41(2,3)4)48-50(38)29-11-13-30(14-12-29)52-20-19-49(5)6/h7-18,21-25H,19-20H2,1-6H3,(H,42,44)(H,43,47)(H2,45,46,51)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205308
PNG
(US9249125, 61)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CC(=O)Nc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C41H41N9O5/c1-26(2)34-25-37(50(48-34)29-9-11-30(12-10-29)54-22-19-49-17-20-53-21-18-49)46-41(52)45-33-13-14-36(32-6-4-3-5-31(32)33)55-39-15-16-42-40(47-39)43-28-8-7-27-23-38(51)44-35(27)24-28/h3-16,24-26H,17-23H2,1-2H3,(H,44,51)(H,42,43,47)(H2,45,46,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205310
PNG
(US9249125, 63)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CNC(=O)c5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C42H43N9O5/c1-42(2,3)36-25-37(51(49-36)29-10-12-30(13-11-29)55-23-20-50-18-21-54-22-19-50)47-41(53)46-34-14-15-35(32-7-5-4-6-31(32)34)56-38-16-17-43-40(48-38)45-28-9-8-27-26-44-39(52)33(27)24-28/h4-17,24-25H,18-23,26H2,1-3H3,(H,44,52)(H,43,45,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205314
PNG
(US9249125, 67)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C42H43N9O4/c1-42(2,3)38-26-40(51(49-38)30-9-11-31(12-10-30)54-23-20-50-18-21-53-22-19-50)47-41(52)46-36-14-15-37(34-7-5-4-6-33(34)36)55-32-16-17-43-39(25-32)45-29-8-13-35-28(24-29)27-44-48-35/h4-17,24-27H,18-23H2,1-3H3,(H,43,45)(H,44,48)(H2,46,47,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205321
PNG
(US9249125, 74)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5n(CCN6CCOCC6)ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C47H53N11O5/c1-47(2,3)42-31-43(58(54-42)35-9-11-36(12-10-35)62-29-24-56-22-27-61-28-23-56)52-46(59)51-39-13-15-41(38-7-5-4-6-37(38)39)63-44-16-17-48-45(53-44)50-34-8-14-40-33(30-34)32-49-57(40)19-18-55-20-25-60-26-21-55/h4-17,30-32H,18-29H2,1-3H3,(H,48,50,53)(H2,51,52,59)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205322
PNG
(US9249125, 75)
Show SMILES Cc1nc2cc(Nc3nccc(Oc4ccc(NC(=O)Nc5cc(nn5-c5ccc(OCCN6CCOCC6)cc5)C(C)(C)C)c5ccccc45)n3)ccc2[nH]1
Show InChI InChI=1S/C42H44N10O4/c1-27-44-34-14-9-28(25-35(34)45-27)46-40-43-18-17-39(49-40)56-36-16-15-33(31-7-5-6-8-32(31)36)47-41(53)48-38-26-37(42(2,3)4)50-52(38)29-10-12-30(13-11-29)55-24-21-51-19-22-54-23-20-51/h5-18,25-26H,19-24H2,1-4H3,(H,44,45)(H,43,46,49)(H2,47,48,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205333
PNG
(US9249125, 86)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(=O)n(CCO)c1
Show InChI InChI=1S/C36H34N10O4/c1-36(2,3)30-19-31(46(44-30)24-9-13-33(48)45(21-24)16-17-47)41-35(49)40-28-11-12-29(26-7-5-4-6-25(26)28)50-32-14-15-37-34(42-32)39-23-8-10-27-22(18-23)20-38-43-27/h4-15,18-21,47H,16-17H2,1-3H3,(H,38,43)(H,37,39,42)(H2,40,41,49)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205336
PNG
(US9249125, 89)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4ccc(=O)n(CCN5CCOCC5)c4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C41H43N11O4/c1-26-21-28(22-27-24-43-48-38(26)27)44-39-42-14-13-36(47-39)56-33-11-10-32(30-7-5-6-8-31(30)33)45-40(54)46-35-23-34(41(2,3)4)49-52(35)29-9-12-37(53)51(25-29)16-15-50-17-19-55-20-18-50/h5-14,21-25H,15-20H2,1-4H3,(H,43,48)(H,42,44,47)(H2,45,46,54)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205337
PNG
(US9249125, 90)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CC(=O)Nc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)nc1
Show InChI InChI=1S/C41H42N10O5/c1-41(2,3)34-24-35(51(49-34)28-10-13-37(43-25-28)55-21-18-50-16-19-54-20-17-50)47-40(53)46-31-11-12-33(30-7-5-4-6-29(30)31)56-38-14-15-42-39(48-38)44-27-9-8-26-22-36(52)45-32(26)23-27/h4-15,23-25H,16-22H2,1-3H3,(H,45,52)(H,42,44,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205338
PNG
(US9249125, 91)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4ccc(OCCN5CCOCC5)nc4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C41H43N11O4/c1-26-21-28(22-27-24-44-49-38(26)27)45-39-42-14-13-37(48-39)56-33-11-10-32(30-7-5-6-8-31(30)33)46-40(53)47-35-23-34(41(2,3)4)50-52(35)29-9-12-36(43-25-29)55-20-17-51-15-18-54-19-16-51/h5-14,21-25H,15-20H2,1-4H3,(H,44,49)(H,42,45,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205339
PNG
(US9249125, 92)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5n(CCN6CCOCC6)ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)nc1
Show InChI InChI=1S/C46H52N12O5/c1-46(2,3)40-29-41(58(54-40)34-9-13-42(48-31-34)62-27-22-56-20-25-61-26-21-56)52-45(59)51-37-10-12-39(36-7-5-4-6-35(36)37)63-43-14-15-47-44(53-43)50-33-8-11-38-32(28-33)30-49-57(38)17-16-55-18-23-60-24-19-55/h4-15,28-31H,16-27H2,1-3H3,(H,47,50,53)(H2,51,52,59)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205298
PNG
(US9249125, 51)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C41H41N9O4/c1-27(2)37-25-40(50(48-37)30-6-5-7-31(23-30)53-21-18-49-16-19-52-20-17-49)46-41(51)45-36-12-13-38(34-9-4-3-8-33(34)36)54-32-14-15-42-39(24-32)44-29-10-11-35-28(22-29)26-43-47-35/h3-15,22-27H,16-21H2,1-2H3,(H,42,44)(H,43,47)(H2,45,46,51)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205302
PNG
(US9249125, 55)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4cc(C)c5[nH]ncc5c4)n3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C41H42N10O4/c1-26(2)35-24-37(51(49-35)30-7-6-8-31(23-30)54-20-17-50-15-18-53-19-16-50)46-41(52)45-34-11-12-36(33-10-5-4-9-32(33)34)55-38-13-14-42-40(47-38)44-29-21-27(3)39-28(22-29)25-43-48-39/h4-14,21-26H,15-20H2,1-3H3,(H,43,48)(H,42,44,47)(H2,45,46,52)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205314
PNG
(US9249125, 67)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C42H43N9O4/c1-42(2,3)38-26-40(51(49-38)30-9-11-31(12-10-30)54-23-20-50-18-21-53-22-19-50)47-41(52)46-36-14-15-37(34-7-5-4-6-33(34)36)55-32-16-17-43-39(25-32)45-29-8-13-35-28(24-29)27-44-48-35/h4-17,24-27H,18-23H2,1-3H3,(H,43,45)(H,44,48)(H2,46,47,52)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205315
PNG
(US9249125, 68)
Show SMILES Cc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(nn4-c4ccc(OCCN5CCOCC5)cc4)C(C)(C)C)c4ccccc34)ccn2)cc2cn[nH]c12
Show InChI InChI=1S/C43H45N9O4/c1-28-23-30(24-29-27-45-49-41(28)29)46-39-25-33(15-16-44-39)56-37-14-13-36(34-7-5-6-8-35(34)37)47-42(53)48-40-26-38(43(2,3)4)50-52(40)31-9-11-32(12-10-31)55-22-19-51-17-20-54-21-18-51/h5-16,23-27H,17-22H2,1-4H3,(H,44,46)(H,45,49)(H2,47,48,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205321
PNG
(US9249125, 74)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5n(CCN6CCOCC6)ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C47H53N11O5/c1-47(2,3)42-31-43(58(54-42)35-9-11-36(12-10-35)62-29-24-56-22-27-61-28-23-56)52-46(59)51-39-13-15-41(38-7-5-4-6-37(38)39)63-44-16-17-48-45(53-44)50-34-8-14-40-33(30-34)32-49-57(40)19-18-55-20-25-60-26-21-55/h4-17,30-32H,18-29H2,1-3H3,(H,48,50,53)(H2,51,52,59)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205322
PNG
(US9249125, 75)
Show SMILES Cc1nc2cc(Nc3nccc(Oc4ccc(NC(=O)Nc5cc(nn5-c5ccc(OCCN6CCOCC6)cc5)C(C)(C)C)c5ccccc45)n3)ccc2[nH]1
Show InChI InChI=1S/C42H44N10O4/c1-27-44-34-14-9-28(25-35(34)45-27)46-40-43-18-17-39(49-40)56-36-16-15-33(31-7-5-6-8-32(31)36)47-41(53)48-38-26-37(42(2,3)4)50-52(38)29-10-12-30(13-11-29)55-24-21-51-19-22-54-23-20-51/h5-18,25-26H,19-24H2,1-4H3,(H,44,45)(H,43,46,49)(H2,47,48,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205337
PNG
(US9249125, 90)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CC(=O)Nc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)nc1
Show InChI InChI=1S/C41H42N10O5/c1-41(2,3)34-24-35(51(49-34)28-10-13-37(43-25-28)55-21-18-50-16-19-54-20-17-50)47-40(53)46-31-11-12-33(30-7-5-4-6-29(30)31)56-38-14-15-42-39(48-38)44-27-9-8-26-22-36(52)45-32(26)23-27/h4-15,23-25H,16-22H2,1-3H3,(H,45,52)(H,42,44,48)(H2,46,47,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205338
PNG
(US9249125, 91)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4ccc(OCCN5CCOCC5)nc4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C41H43N11O4/c1-26-21-28(22-27-24-44-49-38(26)27)45-39-42-14-13-37(48-39)56-33-11-10-32(30-7-5-6-8-31(30)33)46-40(53)47-35-23-34(41(2,3)4)50-52(35)29-9-12-36(43-25-29)55-20-17-51-15-18-54-19-16-51/h5-14,21-25H,15-20H2,1-4H3,(H,44,49)(H,42,45,48)(H2,46,47,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205339
PNG
(US9249125, 92)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5n(CCN6CCOCC6)ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)nc1
Show InChI InChI=1S/C46H52N12O5/c1-46(2,3)40-29-41(58(54-40)34-9-13-42(48-31-34)62-27-22-56-20-25-61-26-21-56)52-45(59)51-37-10-12-39(36-7-5-4-6-35(36)37)63-43-14-15-47-44(53-43)50-33-8-11-38-32(28-33)30-49-57(38)17-16-55-18-23-60-24-19-55/h4-15,28-31H,16-27H2,1-3H3,(H,47,50,53)(H2,51,52,59)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM205305
PNG
(US9249125, 58)
Show SMILES CN(C)CCOc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3cc(C)c4[nH]ncc4c3)c2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C41H43N9O3/c1-26-21-28(22-27-25-43-47-39(26)27)44-37-23-31(17-18-42-37)53-35-16-15-34(32-9-7-8-10-33(32)35)45-40(51)46-38-24-36(41(2,3)4)48-50(38)29-11-13-30(14-12-29)52-20-19-49(5)6/h7-18,21-25H,19-20H2,1-6H3,(H,42,44)(H,43,47)(H2,45,46,51)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the l...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM50156158
PNG
(CHEMBL3781244)
Show SMILES CN(C)CC(=O)Nc1cc(COc2ccc(NC(=O)Nc3cc(nn3-c3ccc(C)cc3)C(C)(C)C)c3ccccc23)ccn1
Show InChI InChI=1S/C35H39N7O3/c1-23-11-13-25(14-12-23)42-32(20-30(40-42)35(2,3)4)39-34(44)37-28-15-16-29(27-10-8-7-9-26(27)28)45-22-24-17-18-36-31(19-24)38-33(43)21-41(5)6/h7-20H,21-22H2,1-6H3,(H,36,38,43)(H2,37,39,44)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 1n/an/an/an/an/an/a



Sygnature Discovery Limited

Curated by ChEMBL


Assay Description
Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...


J Med Chem 59: 1727-46 (2016)


BindingDB Entry DOI: 10.7270/Q2319XRB
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM205331
PNG
(US9249125, 84)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3cc(Nc4ccc5[nH]ncc5c4)ncn3)c3ccccc23)n(n1)-c1ccc(=O)n(CCO)c1
Show InChI InChI=1S/C35H32N10O4/c1-21(2)29-16-32(45(43-29)24-8-12-34(47)44(19-24)13-14-46)41-35(48)40-28-10-11-30(26-6-4-3-5-25(26)28)49-33-17-31(36-20-37-33)39-23-7-9-27-22(15-23)18-38-42-27/h3-12,15-21,46H,13-14H2,1-2H3,(H,38,42)(H,36,37,39)(H2,40,41,48)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<1.5n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the l...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205343
PNG
(US9249125, 14)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3cc(Nc4ccc5[nH]ncc5c4)ncn3)c3ccccc23)n(n1)-c1ccc(=O)n(CCO)c1
Show InChI InChI=1S/C36H34N10O4/c1-36(2,3)30-17-32(46(44-30)24-9-13-34(48)45(20-24)14-15-47)42-35(49)41-28-11-12-29(26-7-5-4-6-25(26)28)50-33-18-31(37-21-38-33)40-23-8-10-27-22(16-23)19-39-43-27/h4-13,16-21,47H,14-15H2,1-3H3,(H,39,43)(H,37,38,40)(H2,41,42,49)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205290
PNG
(US9249125, 43)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4n(CCN5CCOCC5)ncc4c3)n2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C42H44N10O4/c1-42(2,3)37-26-38(52(49-37)30-10-12-31(54-4)13-11-30)47-41(53)46-34-14-16-36(33-8-6-5-7-32(33)34)56-39-17-18-43-40(48-39)45-29-9-15-35-28(25-29)27-44-51(35)20-19-50-21-23-55-24-22-50/h5-18,25-27H,19-24H2,1-4H3,(H,43,45,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205291
PNG
(US9249125, 44)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]nc(OCCN5CCOCC5)c4c3)n2)c2ccccc12)C(C)C
Show InChI InChI=1S/C41H42N10O5/c1-26(2)35-25-37(51(49-35)28-9-11-29(53-3)12-10-28)45-41(52)44-33-14-15-36(31-7-5-4-6-30(31)33)56-38-16-17-42-40(46-38)43-27-8-13-34-32(24-27)39(48-47-34)55-23-20-50-18-21-54-22-19-50/h4-17,24-26H,18-23H2,1-3H3,(H,47,48)(H,42,43,46)(H2,44,45,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205303
PNG
(US9249125, 56)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4cccc(OCCN5CCOCC5)c4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C42H44N10O4/c1-27-22-29(23-28-26-44-49-39(27)28)45-40-43-15-14-38(48-40)56-35-13-12-34(32-10-5-6-11-33(32)35)46-41(53)47-37-25-36(42(2,3)4)50-52(37)30-8-7-9-31(24-30)55-21-18-51-16-19-54-20-17-51/h5-15,22-26H,16-21H2,1-4H3,(H,44,49)(H,43,45,48)(H2,46,47,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205307
PNG
(US9249125, 60)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5COCc5c4)n3)c3ccccc23)n(n1)-c1ccc(OCCN2CCOCC2)cc1
Show InChI InChI=1S/C42H44N8O5/c1-42(2,3)37-25-38(50(48-37)31-10-12-32(13-11-31)54-23-20-49-18-21-52-22-19-49)46-41(51)45-35-14-15-36(34-7-5-4-6-33(34)35)55-39-16-17-43-40(47-39)44-30-9-8-28-26-53-27-29(28)24-30/h4-17,24-25H,18-23,26-27H2,1-3H3,(H,43,44,47)(H2,45,46,51)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205319
PNG
(US9249125, 72)
Show SMILES Cc1n[nH]c2ccc(Nc3nccc(Oc4ccc(NC(=O)Nc5cc(nn5-c5ccc(OCCN6CCOCC6)cc5)C(C)(C)C)c5ccccc45)n3)cc12
Show InChI InChI=1S/C42H44N10O4/c1-27-33-25-28(9-14-35(33)49-48-27)44-40-43-18-17-39(47-40)56-36-16-15-34(31-7-5-6-8-32(31)36)45-41(53)46-38-26-37(42(2,3)4)50-52(38)29-10-12-30(13-11-29)55-24-21-51-19-22-54-23-20-51/h5-18,25-26H,19-24H2,1-4H3,(H,48,49)(H,43,44,47)(H2,45,46,53)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205332
PNG
(US9249125, 85)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)n3)c3ccccc23)n(n1)-c1ccc(=O)n(CCO)c1
Show InChI InChI=1S/C35H32N10O4/c1-21(2)29-18-31(45(43-29)24-8-12-33(47)44(20-24)15-16-46)40-35(48)39-28-10-11-30(26-6-4-3-5-25(26)28)49-32-13-14-36-34(41-32)38-23-7-9-27-22(17-23)19-37-42-27/h3-14,17-21,46H,15-16H2,1-2H3,(H,37,42)(H,36,38,41)(H2,39,40,48)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a<2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205334
PNG
(US9249125, 87)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4ccc(=O)n(CCO)c4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C37H36N10O4/c1-22-17-24(18-23-20-39-44-34(22)23)40-35-38-14-13-32(43-35)51-29-11-10-28(26-7-5-6-8-27(26)29)41-36(50)42-31-19-30(37(2,3)4)45-47(31)25-9-12-33(49)46(21-25)15-16-48/h5-14,17-21,48H,15-16H2,1-4H3,(H,39,44)(H,38,40,43)(H2,41,42,50)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205257
PNG
(US9249125, 10)
Show SMILES Cc1cc(Nc2nccc(Oc3ccc(NC(=O)Nc4cc(nn4-c4cccc(CN5CCCC5=O)c4)C(C)(C)C)c4ccccc34)n2)cc2cn[nH]c12
Show InChI InChI=1S/C41H40N10O3/c1-25-19-28(21-27-23-43-48-38(25)27)44-39-42-17-16-36(47-39)54-33-15-14-32(30-11-5-6-12-31(30)33)45-40(53)46-35-22-34(41(2,3)4)49-51(35)29-10-7-9-26(20-29)24-50-18-8-13-37(50)52/h5-7,9-12,14-17,19-23H,8,13,18,24H2,1-4H3,(H,43,48)(H,42,44,47)(H2,45,46,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205291
PNG
(US9249125, 44)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]nc(OCCN5CCOCC5)c4c3)n2)c2ccccc12)C(C)C
Show InChI InChI=1S/C41H42N10O5/c1-26(2)35-25-37(51(49-35)28-9-11-29(53-3)12-10-28)45-41(52)44-33-14-15-36(31-7-5-4-6-30(31)33)56-38-16-17-42-40(46-38)43-27-8-13-34-32(24-27)39(48-47-34)55-23-20-50-18-21-54-22-19-50/h4-17,24-26H,18-23H2,1-3H3,(H,47,48)(H,42,43,46)(H2,44,45,52)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205293
PNG
(US9249125, 46)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]nc(C(=O)N(C)C)c4c3)n2)c2ccccc12)C(C)C
Show InChI InChI=1S/C38H36N10O4/c1-22(2)31-21-33(48(46-31)24-11-13-25(51-5)14-12-24)42-38(50)41-29-16-17-32(27-9-7-6-8-26(27)29)52-34-18-19-39-37(43-34)40-23-10-15-30-28(20-23)35(45-44-30)36(49)47(3)4/h6-22H,1-5H3,(H,44,45)(H,39,40,43)(H2,41,42,50)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Tyrosine-protein kinase SYK


(Homo sapiens (Human))
BDBM205297
PNG
(US9249125, 50)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5CC(=O)Nc5c4)n3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C42H43N9O5/c1-42(2,3)36-26-37(51(49-36)29-7-6-8-30(25-29)55-22-19-50-17-20-54-21-18-50)47-41(53)46-33-13-14-35(32-10-5-4-9-31(32)33)56-39-15-16-43-40(48-39)44-28-12-11-27-23-38(52)45-34(27)24-28/h4-16,24-26H,17-23H2,1-3H3,(H,45,52)(H,43,44,48)(H2,46,47,53)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM205298
PNG
(US9249125, 51)
Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C41H41N9O4/c1-27(2)37-25-40(50(48-37)30-6-5-7-31(23-30)53-21-18-49-16-19-52-20-17-49)46-41(51)45-36-12-13-38(34-9-4-3-8-33(34)36)54-32-14-15-42-39(24-32)44-29-10-11-35-28(22-29)26-43-47-35/h3-15,22-27H,16-21H2,1-2H3,(H,42,44)(H,43,47)(H2,45,46,51)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the l...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205255
PNG
(US9249125, 8)
Show SMILES COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]ncc4c3)n2)c2ccccc12)C1CCOC1
Show InChI InChI=1/C36H31N9O4/c1-47-26-9-7-25(8-10-26)45-33(19-31(44-45)22-15-17-48-21-22)41-36(46)40-30-12-13-32(28-5-3-2-4-27(28)30)49-34-14-16-37-35(42-34)39-24-6-11-29-23(18-24)20-38-43-29/h2-14,16,18-20,22H,15,17,21H2,1H3,(H,38,43)(H,37,39,42)(H2,40,41,46)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM206344
PNG
(US9260410, 2)
Show SMILES CC(=O)Nc1cc(COc2ccc(NC(=O)Nc3cc(nn3-c3ccc(C)cc3)C(C)(C)C)c3ccccc23)ccn1
Show InChI InChI=1S/C33H34N6O3/c1-21-10-12-24(13-11-21)39-31(19-29(38-39)33(3,4)5)37-32(41)36-27-14-15-28(26-9-7-6-8-25(26)27)42-20-23-16-17-34-30(18-23)35-22(2)40/h6-19H,20H2,1-5H3,(H,34,35,40)(H2,36,37,41)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PubMed
n/an/a 2n/an/an/an/an/an/a



Sygnature Discovery Limited

Curated by ChEMBL


Assay Description
Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...


J Med Chem 59: 1727-46 (2016)


BindingDB Entry DOI: 10.7270/Q2319XRB
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM50156160
PNG
(CHEMBL3780667)
Show SMILES Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCc2ccnc(NC(=O)CN3CCOCC3)c2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C37H41N7O4/c1-25-9-11-27(12-10-25)44-34(22-32(42-44)37(2,3)4)41-36(46)39-30-13-14-31(29-8-6-5-7-28(29)30)48-24-26-15-16-38-33(21-26)40-35(45)23-43-17-19-47-20-18-43/h5-16,21-22H,17-20,23-24H2,1-4H3,(H,38,40,45)(H2,39,41,46)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
Purchase

CHEMBL
PC cid
PC sid
PDB
UniChem

Patents

PubMed
n/an/a 2n/an/an/an/an/an/a



Sygnature Discovery Limited

Curated by ChEMBL


Assay Description
Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...


J Med Chem 59: 1727-46 (2016)


BindingDB Entry DOI: 10.7270/Q2319XRB
More data for this
Ligand-Target Pair
Mitogen-activated protein kinase 14


(Homo sapiens (Human))
BDBM50156162
PNG
(CHEMBL3781245)
Show SMILES CSCC(=O)Nc1cc(COc2ccc(NC(=O)Nc3cc(nn3-c3ccc(C)cc3)C(C)(C)C)c3ccccc23)ccn1
Show InChI InChI=1S/C34H36N6O3S/c1-22-10-12-24(13-11-22)40-31(19-29(39-40)34(2,3)4)38-33(42)36-27-14-15-28(26-9-7-6-8-25(26)27)43-20-23-16-17-35-30(18-23)37-32(41)21-44-5/h6-19H,20-21H2,1-5H3,(H,35,37,41)(H2,36,38,42)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

B.MOAD
DrugBank
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
PubMed
n/an/a 2n/an/an/an/an/an/a



Sygnature Discovery Limited

Curated by ChEMBL


Assay Description
Inhibition of human recombinant p38 alpha assessed as phosphorylation of MAPKAP-K2 preincubated for 2 hrs followed by FRET peptide and MAPKAP-K2 addi...


J Med Chem 59: 1727-46 (2016)


BindingDB Entry DOI: 10.7270/Q2319XRB
More data for this
Ligand-Target Pair
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform


(Homo sapiens (Human))
BDBM200638
PNG
(US9227977, Compound (I))
Show SMILES COCCOCCOCC#Cc1cccc2nc(Cn3nc(-c4cc(O)cc(F)c4)c4c(N)ncnc34)n(Cc3ccccc3C(F)(F)F)c(=O)c12
Show InChI InChI=1S/C36H31F4N7O5/c1-50-12-13-52-15-14-51-11-5-8-22-7-4-10-28-30(22)35(49)46(19-23-6-2-3-9-27(23)36(38,39)40)29(44-28)20-47-34-31(33(41)42-21-43-34)32(45-47)24-16-25(37)18-26(48)17-24/h2-4,6-7,9-10,16-18,21,48H,11-15,19-20H2,1H3,(H2,41,42,43)
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.5n/an/an/an/an/an/a



Respivert Ltd.

US Patent


Assay Description
The PI3K enzymes catalyse the phosphorylation of phosphatidylinositol 4,5-biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3) in the...


US Patent US9227977 (2016)


BindingDB Entry DOI: 10.7270/Q2BZ64WZ
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205261
PNG
(US9249125, 13)
Show SMILES COc1ccc(cn1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc4[nH]ncc4c3)n2)c2ccccc12)C(C)(C)C
Show InChI InChI=1S/C35H32N10O3/c1-35(2,3)29-18-30(45(44-29)23-10-14-31(47-4)37-20-23)41-34(46)40-27-12-13-28(25-8-6-5-7-24(25)27)48-32-15-16-36-33(42-32)39-22-9-11-26-21(17-22)19-38-43-26/h5-20H,1-4H3,(H,38,43)(H,36,39,42)(H2,40,41,46)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src


(Homo sapiens (Human))
BDBM205299
PNG
(US9249125, 52)
Show SMILES CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc5[nH]ncc5c4)c3)c3ccccc23)n(n1)-c1cccc(OCCN2CCOCC2)c1
Show InChI InChI=1S/C42H43N9O4/c1-42(2,3)38-26-40(51(49-38)30-7-6-8-31(24-30)54-22-19-50-17-20-53-21-18-50)47-41(52)46-36-13-14-37(34-10-5-4-9-33(34)36)55-32-15-16-43-39(25-32)45-29-11-12-35-28(23-29)27-44-48-35/h4-16,23-27H,17-22H2,1-3H3,(H,43,45)(H,44,48)(H2,46,47,52)
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3n/an/an/an/an/an/a



RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED

US Patent


Assay Description
The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...


US Patent US9249125 (2016)


BindingDB Entry DOI: 10.7270/Q2CN72QG
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 475 total )  |  Next  |  Last  >>
Jump to: